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Abstract. Alzheimer's Disease (AD), Parkinson, and other neurodegenerative diseases are a major health 
problem nowadays. However, in many cases, current therapies are merely palliative and only temporarily slow 
cognitive decline. In this sense, the discovery of new drugs for the treatment of neurodegenerative diseases is a 
goal of the major importance. Public databases, like ChEMBL, contain a large amount of data about 
multiplexing assays of inhibitors of a group of enzymes with special relevance in central nervous system. Mono 
Amino Oxidases (MAOs), Acetyl Cholinesterase (AChE), Glycogen Synthase Kinase-3 (GSK-3), AChE 
(AChE), and 5α-reductases (5αRs). This data conform an important information source for the application of 
multi-target computational models. However, almost all the computational models known focus in only one 
target. In this work, we developed linear multi-target QSAR models (mt-QSAR) for inhibitors of 8 different 
enzymes promising in the treatment of different neurodegenerative diseases. In so doing, we combined by the 
first time the software DRAGON with Moving Average parameters with this objective. The best DRAGON 
model found predict with very high accuracy, specificity, and sensitivity >90% a very large data set >10000 
cases in training and validation series. 
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1. INTRODUCTION 
The discovery of new compounds for the treatment of neurodegenerative diseases is a goal of the major 
importance for medicinal chemistry and biopharmaceutical industry. In fact, neurodegenerative diseases have a 
high negative impact in personal and public health. For instance, Alzheimer´s disease [1] is a serious and 
degenerative disorder that causes a gradual loss of neurons, and in spite of the efforts realized by the big 
pharmaceutical companies of the world, the origin of this pathology is still not very clear. β-amyloid (Aβ) is an 
important protein implicated in the pathogenesis of AD, but the mechanism by which it causes neurotoxicity is 
still unknown [2, 3]. Recent research efforts have led to several hypotheses to explain AD. Amyloid β toxicity 
is believed to play a primary role in the development of AD [4]. A group of neuronal enzymes stands out 
between the potential targets of drugs useful in the treatment of these diseases. In fact, the functions of neuronal 
enzymes and its implication in various human diseases have triggered an active search for potent and selective 
neuronal enzyme inhibitors [5] in the last years. Mono Amino Oxidases (MAOs), Acetyl Cholinesterase 
(AChE), Glycogen Synthase Kinase-3 (GSK-3), Acetyl Cholinesterase (AChE), and 5α-reductases (5αRs); 
stand out among the more promising enzymes in this sense. GSK-3 has two isoforms, GSK-3α and GSK-3β [6]. 
In particular, GSK-3β is well known to play critical roles in oxidative stress-induced neurodegenerative 
diseases such as AD [7, 8]. A more comprehensive understanding of the mechanistic basis for GSK-3 isoform-
specific functions could lead to the development of isoform-specific inhibitors [9]. MAOs are important 
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flavoenzymes with two isoforms (MAO-A and MAO-B); which are responsible for the oxidative deamination 
of neurotransmitters and dietary amines and thus involved in neurodegenerative diseases. MAO-A has a higher 
affinity for serotonin and norepinephrine whereas MAO-B preferentially deaminates phenylethylamine and 
benzylamine. Therefore, selective MAO-A inhibitors (i.e. chlorgyline) are used in the treatment of neurological 
disorders such as depression, whereas the MAO-B inhibitors (i.e. selegiline) are useful in the treatment of AD 
and Parkinson’s. All of these aspects have led to an intensive search for novel MAO inhibitors (MAOIs) and 
this effort has increased considerably in recent years. On the other hand, AChE activity is associated with 
neuritic plaques (NPs) and neurofibrillary tangles (NFTs) in AD brains. AChE inhibitors (AChIs) are promising 
drugs in clinical practice for the treatment of AD. Recently, Bond et al reviewed the effectiveness and cost-
effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of AD [10]. Last, 5αRs 
are a family of isozymes expressed in a seveal tissues including the central nervous system. Very recently, 
Traish [11] performed a comprehensive literature search from 1970-2011 via PubMed and summarized the 
relevant information with special emphasis on the central nervous systems.  
Thus, the rational design of new enzyme inhibitors for the treatment of neurodegenerative disease constitutes 
a major goal. In our opinion, Quantitative Structure-Activity Relationships (QSAR) techniques may be of help 
in this sense. Regrettably, almost current QSAR techniques are able to predict new outcomes only for one 
specific assay. In our opinion, we can evade this problem developing new Multi-target/Multiplexing QSAR 
models (mt-QSAR/mx-QSAR). These methods are especially powerful when we need to process very large 
collections of compounds assayed against multiple molecular or cellular targets in different assay conditions 
(mj) as is the case of CHEMBL [12, 13]. This step may be of the major relevance for the future of QSAR. 
Notably, mt-QSAR models are able to predict the results of the assay of different drugs for multiple targets. 
However, mt-QSAR models are unable to predict different results for a given series of targets when we change 
the set of specific assay conditions for each target. Fortunately, the new class of mx-QSAR models applies not 
only to different targets but also to different multiplexing assay conditions (mj) for all targets. Specifically, we 
have reported the first mx-QSAR model for multiplexing assays of anti-Alzheimer, anti-parasitic, anti-fungi, 
and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines [14].  
QSAR techniques are based on the use of molecular descriptors, which are numerical series that codify useful 
chemical information and enable correlations between statistical and biological properties [15, 16]. We can use 
different topological indices (TIs) of molecular graphs (G) to speed up the process of codification of the 
molecular structure of drugs in QSAR studies. In particular, Galvez’s charge transfer indices and their different 
variants (G-like indices) have been demonstrated to be very useful in QSAR/QSPR studies of small molecules. 
For instance, the HIV-1 RT inhibitory activity of thiazolidinones has been analyzed with different TIs and G-
like values together with other TIs have been found to be accurate predicting the activity of these compounds 
[17].  G-like indices also overtook 11 kinds of molecular descriptors in one study of inhibitors of flavonoids 
aldose reductase enzyme [18]. For a detailed revision of many QSAR models using TIs (including Gk indices) 
see the recent in-depth review published in Chemical Reviews by Galvez’s group [19]. In addition, G-like 
indices have been found to be also useful for study complex bio-molecular networks and not only chemical 
structure. For instance, González-Díaz et al. [20] used G-like indices to study different classes of networks 
found in drug research, nature, technology, and social-legal sciences. Important QSAR studies of the enzymes 
under study in this work have been published before. For instance, Santana and Uriarte et al. [21-23] have 
published several QSAR and experimental studies of new MAO inhibitors. However, there are not mt-QSAR 
models based on G-like indices for all these enzymes together. In this work, we used by the first time molecular 
descriptors calculated developed by Galvez et al. to develop one mt-QSAR model for inhibitors of 8 different 
enzymes. The best model found use as input we used moving average operators to predict with very high 




2. MATERIALS AND METHODS 
2.1 Computational methods 
Regrettably, almost current Quantitative Structure-Activity Relationships (QSAR) techniques are able to 
predict new outcomes only for one specific assay. In our opinion, we can evade this problem developing new 
Multi-target/Multiplexing QSAR models (mt-QSAR/mx-QSAR). These methods are especially powerful 
when we need to process very large collections of compounds assayed against multiple molecular or cellular 
targets in the different jth assay conditions (cj); as is the case of CHEMBL [12, 13]. This step may be of the 
major relevance for the future of QSAR. Notably, mt-QSAR models are able to predict the results of the assay 
of different drugs for multiple targets. However, mt-QSAR models are unable to predict different results for a 
given series of targets when we change the set of specific assay conditions for each target. Fortunately, the 
new class of mx-QSAR models applies not only to different targets but also to different multiplexing assay 
conditions (cj) for all targets. Specifically, we have reported the first mx-QSAR model for multiplexing assays 
of anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, 
and in different cellular lines [14]. In a first step, we need to calculate the molecular descriptors using Di of a 
given ith compound using one or more software for generation of molecular descriptors. In a second step, we 
expand the raw dataset of molecular descriptors adding new variables ΔDij = Di – <Dij>. Next, we upload this 
preprocessed data to one Statistics or Machine Learning software to seek the model. The linear mt-QSAR 
model based on moving averages and LDA has the following general form: 
































Where, Sij is a numerical score of the biological activity of the ith compound measured under the jth assay 
defined by the set of conditions cj. In these models, the average <Dij> = <Di(cj)>, used to calculate ΔDij values, 
is the average of the Di for different compounds and do not runs over a time domain but over a set of molecular 
descriptors that obey a given boundary condition cj. These deviation-like parameters ΔDij are inspired in the 
idea of moving averages used in time series analysis [24]. The idea of using moving average operators comes 
from the seminar works on time series analysis published by Box and Jenkins [25]. More recently, González-
Díaz et al. [26, 27] have used moving average operators to construct mt-QSAR models. See also the excellent 
works published by Speck-Planche and Cordeiro et al. [28-33]. 
 
3. RESULTS AND DISCUSSION 
3.1. Multi-target DRAGON model of drug-neuroenzyme interaction 
The outcome of multiplexing neural enzyme inhibition assays depend both on drug structure and the set of 
assay conditions selected (mj) [34]. In this work, we report the first mx-QSAR model capable of predict 
whether a drug with a determined molecular structure may give or not a positive result in different 
multiplexing assay conditions mj. These models are expected to give different classification probabilities of 
the compound for different: organisms (ot), biological assays (au), molecular or cellular targets (te). The best 
mt-QSAR model found using DRAGON was the following:  
( ) ( ) ( ) ( ) ( )
( ) ( ) ( )




















S(mj) = S(di, au, ot, te) is a real-valued variable that scores the propensity of the drug to be active in multiplex 
pharmacological assays of the drug di carried out on the conditions selected mj => assay = au, organism = ot, and 
target enzyme te. The statistical parameters for the above equation in training are: Number of cases used to train 
the model (N), Canonical Regression Coefficient (Rc), Sensitivity (Sn), Specificity (Sp), and Accuracy (Ac) 
[24]. The probability cut-off for this LDA model is ip1(mj) > 0.5 => Ci(mj) = 1. It means that the ith drug (di) 
predicted by the model with probability > 0.5 are expected to inhibit the enzyme present in the jth assays carry 
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out under the given set of conditions mj. In Table 1, we explain in detail the different terms of this equation. 
Online supplementary material files contain detailed lists of results for all cases analyzed.  
Table 1 comes about here  
This linear equation presented good results both in training and external validation series with overall 
Accuracy in training series above 90% (see Table 2). According to previous reports [35-43] values accuracy 
higher than 75% are acceptable for LDA-QSAR models. The reader should be aware that N here is not number 
of compounds but number of statistical cases. One compound may lead to 1 or more statistical cases because it 
may give different outcomes for alternative biological assays carried out in different organisms and used 
different enzymes as targets [44]. 
Table 2 comes about here  
3.1.1 Prediction of interaction with other neuro-enzymes 
An additional use of mt-DRAGON model was to carry out the “in silico” or virtual screening of the new 
interactions with respect to all other enzymes used in this model. It may help to found new interactions for these 
drugs or discard possible toxicological effects depending on the other interactions predicted and/or discarded for 
these compounds. This type of experiment is of the major importance due to the cost in terms of animal 
sacrifice, time, materials and human resources of the experimental assay of all compounds against all these 
targets, see recent reviews by Duardo-Sanchez et al. [45-48].  
Using this model we can predict the different relationships between the drug-protein interactions [49, 50]. We 
can reach this goal because the model predicts all neuro enzymes as non-active or moderate activity with 
respect to all compounds that are used in the model. Another important goal, is that the model predicted all the 
before results on Homo sapiens organism. In Table 3, we depict all the labels of the experimental parameters, 
target enzymes, and organism.  
Table 3 comes about here 
CONCLUSION 
The functions of neural enzymes and its implication in various human diseases have triggered an active search 
for potent and selective neural enzyme inhibitors. Theoretical mt-QSAR models based on LDA and DRAGON 
descriptors may become a useful tool in this sense. Nowadays, theoretical studies such as QSAR models have 
become a very useful tool in this context to substantially reduce time and resources consuming experiments. In 
this work we developed a new LDA model using the Dragon descriptors, with a large data base using about 
20000 different drugs obtained from the ChEMBL server. We conclude that a large database gives a much more 
precise model; the use of tools such as ChEMBL database enables us to develop models with large data bases, 
and this helps us to make the results more reliable. 
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FIGURES AND TABLES PRESENTS IN THIS MANUSCRIPT 
Table 1. Details of the DRAGON mt-QSAR model for neural enzyme inhibitors 
Step Coeff. Value Variable Expansiona Symbolsb  
0 a0 6.98560 - - - 
1 c1 -1.16744 <D1(e)> - D1 = GGI2 
2 c2 -7.25512 <D2(a)> - D2 = JGI1 
3 d3 0.67000 ΔD3(e) = D3 - <D3(e)> D3 = GGI4 
4 d4 0.06642 ΔD4(a) = D5 - <D5(a)> D4 = GGI1 
5 d5 -0.28877 ΔD5(a) = D5 - <D5(a)> D5 = GGI3 
6 d6 -2.63365 ΔD6(a) = D6 - <D6(a)> D6 = GGI10 
7 d4 2.42299 ΔD7(a) = D7 - <D7(a)> D7 = JGT 
8 d8 0.75944 ΔD8(o) = D8 - <D8(o)> D8 = GGI7 
9 d9 5.87857 ΔD9(o) = D9 - <D9(o)> D9 = JGT 
a <Di(mj)> = SUM(Di)/n1(mj), see materials and methods; b Symbols of G-like descriptors calculated by the software DRAGON. 
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Table 2. Results of different DRAGON multi-target classification models 
Drug-Enzyme Train Statistical 
interaction Active Non-Active % Parameter 
Active 9231 1020 90.0 Sn 
Non-Active 771 8289 91.5 Sp 
   90.7 Ac 
Drug-Enzyme Validation Statistical 
interaction % % % Parameter 
Active 3145 324 90.7 Sn 
Non-Active 245 2775 91.9 Sp 
   91.2 Ac 
a Sensitivity = Sn = Positive Correct/Positive Total; Specificity = Sp = Negative Correct / Negative Total; Accuracy = Ac = Total 
Correct / Overall Total 
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Table 3. Labels of the experimental parameters, target enzymes, and organisms  
Label Target Assay Standard (Unit) 
1 AChE 12 cKi (nM)  
2 Gamma-secretase subunit APH-1A 13 EC50 (nM)  
3 Gamma-secretase subunit APH-1B 14 ED50 (nM)  
4 Gamma-secretase subunit PEN-2 16 IC50 (microM)  
5 Glycogen synthase kinase-3 alpha 17 IC50 (nM)  
6 Glycogen synthase kinase-3 beta 20 Inhibition (%)  
7 Monoamine oxidase A 26 Inhibition ((nM of H202) min-1 (ug of protein)-1)  
8 Monoamine oxidase B 27 Inhibition (ug)  
Label Organism 30 Ki (nM)  
1 Bos taurus 34 Ki   
2 Electrophorus electricus 37 Log IC50   
3 Homo sapiens 39 Log Ki (M)  
4 Mus musculus 40 Log Ki   
5 Rattus norvegicus 42 Relative activity   
6 Torpedo californica 43 Selectivity (nM)  
Assay Standard (Unit) 44 Selectivity   
1 Activity (%)  48 Selectivity coefficient   
4 Activity (nM)  49 Selectivity index   
5 Activity (nM min-1 mg-1)  50 Selectivity ratio   
7 Activity (ug)  53 SI   
9 Activity   55 Specific activity (%)  
10 A-selectivity   56 Specific activity (nM Pi min-1 (mg of protein)-1)  
 
